According to the Complaint, MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. The Company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma is a late-stage pharmaceutical company that focuses on the development of various therapies for the treatment of cancer. MEI Pharma's clinical drug candidates include, among others, Pracinostat, an oral histone deacetylase inhibitor.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) MEI Pharma had overstated Pracinostat's potential efficacy as an AML treatment for the target population; (ii) consequently, the Phase 3 Pracinostat Trial was unlikely to meet its primary endpoint of overall survival; (iii) all the foregoing, once revealed, was foreseeably likely to have a material negative impact on the Company's financial condition and prospects for Pracinostat; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

On December 17, 2020, the Court issued an Order appointing Lead Plaintiff and Counsel. This case was voluntarily dismissed on February 16, 2021.